NASDAQ:KNSA Kiniksa Pharmaceuticals Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Kiniksa Pharmaceuticals Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $17.24 +0.34 (+2.01 %) (As of 09/18/2020 12:00 AM ET) Add Compare Share Today's Range$16.81Now: $17.24▼$17.5350-Day Range$15.37MA: $17.55▼$20.0052-Week Range$5.01Now: $17.24▼$28.67Volume1.35 million shsAverage Volume314,755 shsMarket Capitalization$1.17 billionP/E RatioN/ADividend YieldN/ABeta-0.23 ProfileAnalyst RatingsChartCompetitorsEarningsInsider TradesInstitutional OwnershipHeadlinesShort InterestSocial Media Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on the discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its clinical-stage product candidates include Rilonacept, which is in Phase II clinical trials for the treatment of recurrent pericarditis, an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; and KPL-716, a monoclonal antibody, which is in Phase 1a/1b clinical trial for the treatment of prurigo nodularis and atopic dermatitis. The company's preclinical product candidates comprise KPL-404, a monoclonal antibody inhibitor of the CD40 co-stimulatory receptor; and KPL-045, a monoclonal antibody inhibitor of the CD30 ligand co-stimulatory molecule. Kiniksa Pharmaceuticals, Ltd. was founded in 2015 and is based in Hamilton, Bermuda.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingKiniksa Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $32.00, Kiniksa Pharmaceuticals has a forecasted upside of 85.6% from its current price of $17.24.Amount of Analyst CoverageKiniksa Pharmaceuticals has only been the subject of 2 research reports in the past 90 days. Previous Next 2.4 Community Rank Outperform VotesKiniksa Pharmaceuticals has received 148 “outperform” votes. (Add your “outperform” vote.)Underperform VotesKiniksa Pharmaceuticals has received 158 “underperform” votes. (Add your “underperform” vote.)Community SentimentKiniksa Pharmaceuticals has received 51.63% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Kiniksa Pharmaceuticals and other stocks. Vote “Outperform” if you believe KNSA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe KNSA will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldKiniksa Pharmaceuticals does not currently pay a dividend.Dividend GrowthKiniksa Pharmaceuticals does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Kiniksa Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $750,673.00 in company stock.Percentage Held by Insiders59.92% of the stock of Kiniksa Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 31.04% of the stock of Kiniksa Pharmaceuticals is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Kiniksa Pharmaceuticals are expected to decrease in the coming year, from ($2.30) to ($2.35) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Kiniksa Pharmaceuticals is -7.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Kiniksa Pharmaceuticals is -7.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKiniksa Pharmaceuticals has a P/B Ratio of 4.20. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.38 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:KNSA Previous Symbol CUSIPN/A CIKN/A Webwww.kiniksa.com Phone44-80-8189-6257Debt Debt-to-Equity RatioN/A Current Ratio12.87 Quick Ratio12.87Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.10 per share Price / Book4.20Profitability EPS (Most Recent Fiscal Year)($2.99) Net Income$-161,870,000.00 Net MarginsN/A Return on Equity-52.59% Return on Assets-47.49%Miscellaneous Employees111 Outstanding Shares67,874,000Market Cap$1.17 billion Next Earnings Date10/26/2020 (Estimated) OptionableNot Optionable $17.24 +0.34 (+2.01 %) (As of 09/18/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive KNSA News and Ratings via Email Sign-up to receive the latest news and ratings for KNSA and its competitors with MarketBeat's FREE daily newsletter. Kiniksa Pharmaceuticals (NASDAQ:KNSA) Frequently Asked Questions How has Kiniksa Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)? Kiniksa Pharmaceuticals' stock was trading at $16.10 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, KNSA stock has increased by 7.1% and is now trading at $17.24. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Kiniksa Pharmaceuticals? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kiniksa Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Kiniksa Pharmaceuticals. When is Kiniksa Pharmaceuticals' next earnings date? Kiniksa Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, October 26th 2020. View our earnings forecast for Kiniksa Pharmaceuticals. How were Kiniksa Pharmaceuticals' earnings last quarter? Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA) announced its quarterly earnings results on Thursday, July, 30th. The company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.63) by $0.02. View Kiniksa Pharmaceuticals' earnings history. What price target have analysts set for KNSA? 4 Wall Street analysts have issued 12 month price targets for Kiniksa Pharmaceuticals' stock. Their forecasts range from $24.00 to $40.00. On average, they anticipate Kiniksa Pharmaceuticals' stock price to reach $32.00 in the next twelve months. This suggests a possible upside of 85.6% from the stock's current price. View analysts' price targets for Kiniksa Pharmaceuticals. Are investors shorting Kiniksa Pharmaceuticals? Kiniksa Pharmaceuticals saw a increase in short interest in the month of August. As of August 31st, there was short interest totaling 2,880,000 shares, an increase of 14.3% from the August 15th total of 2,520,000 shares. Based on an average trading volume of 358,600 shares, the days-to-cover ratio is presently 8.0 days. View Kiniksa Pharmaceuticals' Short Interest. Who are some of Kiniksa Pharmaceuticals' key competitors? Some companies that are related to Kiniksa Pharmaceuticals include Zai Lab (ZLAB), HUTCHISON CHINA/S (HCM), Arrowhead Pharmaceuticals (ARWR), Blueprint Medicines (BPMC), Legend Biotech (LEGN), Allakos (ALLK), Arena Pharmaceuticals (ARNA), FibroGen (FGEN), Evotec (EVTCY), ChemoCentryx (CCXI), Biohaven Pharmaceutical (BHVN), Amicus Therapeutics (FOLD), Turning Point Therapeutics (TPTX), Nektar Therapeutics (NKTR) and Schrodinger (SDGR). View all competitors. What other stocks do shareholders of Kiniksa Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Kiniksa Pharmaceuticals investors own include Exelixis (EXEL), Crispr Therapeutics (CRSP), VBI Vaccines (VBIV), Clovis Oncology (CLVS), NVIDIA (NVDA), Pfizer (PFE), Vaxart (VXRT), Dicerna Pharmaceuticals (DRNA), ImmunoGen (IMGN) and SCYNEXIS (SCYX). Who are Kiniksa Pharmaceuticals' key executives? Kiniksa Pharmaceuticals' management team includes the following people: Mr. Sanj K. Patel, CEO & Chairman (Age 49)Mr. Stephen Mahoney, Pres & COO (Age 47)Dr. John F. Paolini, Chief Medical Officer (Age 53)Mr. Chris Heberlig, Exec. VP & CFO (Age 43)Mark Ragosa C.F.A., VP of Investor Relations When did Kiniksa Pharmaceuticals IPO? (KNSA) raised $126 million in an initial public offering on Thursday, May 24th 2018. The company issued 7,000,000 shares at $17.00-$19.00 per share. Goldman Sachs and J.P. Morgan served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers. What is Kiniksa Pharmaceuticals' stock symbol? Kiniksa Pharmaceuticals trades on the NASDAQ under the ticker symbol "KNSA." Who are Kiniksa Pharmaceuticals' major shareholders? Kiniksa Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Hillhouse Capital Advisors LTD. (4.10%), Vanguard Group Inc. (2.88%), Sofinnova Investments Inc. (1.36%), Federated Hermes Inc. (0.66%), Opaleye Management Inc. (0.58%) and Nuveen Asset Management LLC (0.48%). Company insiders that own Kiniksa Pharmaceuticals stock include John F Paolini, Sanj K Patel and Thomas W Beetham. View institutional ownership trends for Kiniksa Pharmaceuticals. Which major investors are selling Kiniksa Pharmaceuticals stock? KNSA stock was sold by a variety of institutional investors in the last quarter, including Ikarian Capital LLC, Sofinnova Investments Inc., Hudson Bay Capital Management LP, Jacobs Levy Equity Management Inc., Strs Ohio, Leap Investments LP, and Exane Derivatives. Company insiders that have sold Kiniksa Pharmaceuticals company stock in the last year include John F Paolini, Sanj K Patel, and Thomas W Beetham. View insider buying and selling activity for Kiniksa Pharmaceuticals. Which major investors are buying Kiniksa Pharmaceuticals stock? KNSA stock was bought by a variety of institutional investors in the last quarter, including Hillhouse Capital Advisors LTD., Vanguard Group Inc., Opaleye Management Inc., Federated Hermes Inc., FMR LLC, FMR LLC, Bank of America Corp DE, and Alyeska Investment Group L.P.. View insider buying and selling activity for Kiniksa Pharmaceuticals. How do I buy shares of Kiniksa Pharmaceuticals? Shares of KNSA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Kiniksa Pharmaceuticals' stock price today? One share of KNSA stock can currently be purchased for approximately $17.24. How big of a company is Kiniksa Pharmaceuticals? Kiniksa Pharmaceuticals has a market capitalization of $1.17 billion. The company earns $-161,870,000.00 in net income (profit) each year or ($2.99) on an earnings per share basis. Kiniksa Pharmaceuticals employs 111 workers across the globe. What is Kiniksa Pharmaceuticals' official website? The official website for Kiniksa Pharmaceuticals is www.kiniksa.com. How can I contact Kiniksa Pharmaceuticals? Kiniksa Pharmaceuticals' mailing address is CLARENDON HOUSE 2 CHURCH STREET, HAMILTON D0, HM11. The company can be reached via phone at 44-80-8189-6257 or via email at [email protected] This page was last updated on 9/18/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
